Antineoplastic Agents: Cytotoxic Agents: Miscellaneous
ICAMP1 “Campto injection” 20 mg/ml; 5 ml/vial
適應症：晚期性大腸直腸癌之第一線治療藥物、與5-FU及folinic acid合併，使用於未曾接受過化學治療之患者、單獨使用於曾接受5-FU療程治療無效之患者。
Usual dose:
Colorectal cancer-combination therapy:
6-wk cycle with bolus 5-fluorouracil/leucovorin (starting dose and modified dose levels (mg/m2)): 125 mg/m2 IV over 90 min days 1, 8, 15, 22 (dose level-1= 100 and dose level-2= 75); leucovorin 20 mg/m2 IV bolus on days 1, 8, 15, 22 (no change for dose level-1 and 2); 5-fluorouracil 500 mg/m2 IV bolus on days 1, 8, 15, 22 (dose level -1= 400, dose level-2= 300); next cycle begins on day 43.
Adverse effect:
Common: alopecia.
Serious: diarrhea, N/V, hepatic dysfunction, infection, grade 3 and 4, neutropenic fever, severe myelosuppression.
健保使用規範：限轉移性大腸直腸癌之第一線治療藥物：1.與5-FU及folinic acid合併，使用於未曾接受過化學治療之患者；2.單獨使用於曾接受5-FU療程治療無效之患者。